Education
About Us
Working with TipRanks
Follow Us
Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥970.00 - ¥1,508.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)63.87K
Market Cap
¥45.08B
Enterprise Value¥52.96B
Total Cash (Recent Filing)¥2.15B
Total Debt (Recent Filing)¥11.94B
Price to Earnings (P/E)18.3
Beta0.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,096,880
10 Day Avg. Volume54,390
30 Day Avg. Volume63,866
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.58
Price to Sales (P/S)0.59
P/FCF Ratio-31.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth indicates continued demand for the firm's drugs and OTC products, supporting scale benefits and market presence. Over 2–6 months this trend underpins predictable sales streams, helping fund R&D and operations even as margins fluctuate.
Diversified Product PortfolioA mix of prescription and over-the-counter offerings across multiple therapeutic areas reduces reliance on any single product or channel. This structural diversification supports steadier revenue, multiple distribution routes, and resilience to product-specific setbacks over the medium term.
Stable Capital Structure And Operating MarginsA stable equity base and continued positive operating margins provide financial cushioning against shocks. Even with margin pressure, positive EBIT/EBITDA indicates core operations generate earnings capacity to service obligations and fund near-term investments.
Bears Say
Margin CompressionSignificant declines in gross and net margins signal rising costs or pricing pressure that erode profitability. Persisting margin squeeze will limit retained earnings, reduce reinvestment capacity for R&D or manufacturing, and weaken long-term return on capital if not arrested.
Rising Leverage And Falling ROEIncreasing leverage alongside sharply lower ROE points to deteriorating capital efficiency and greater financial risk. Over months this reduces strategic flexibility, raises interest exposure, and makes funding growth or defending margins more reliant on external financing.
Negative Free Cash FlowMaterial negative free cash flow and a steep decline in FCF growth constrain the company’s ability to self-fund capex, R&D, or shareholder returns. Persistent cash deficits increase dependence on debt or equity issuance, amplifying dilution or leverage risks.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥970.00 and its highest was ¥1508.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥45.08B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥20 which represents an annual dividend yield of 2.75%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 30,096,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---